Literature DB >> 21671028

Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?

Peter F Zipfel1, Gunter Wolf, Ulrike John, Karim Kentouche, Christine Skerka.   

Abstract

Thrombotic microangiopathies (TMA) represent a spectrum of related disorders associated with newly formed thrombi that block perfusion and thus affect the function of either renal or neurological organs and tissue. Recent years have seen a dramatic development in the field of TMA and for the two major forms hemolytic uremic syndrome (HUS) and thrombocytopenic purpura (TTP), new genetic causes and also autoimmune forms have been identified. This development indicates a similar pathophysiology and suggests that the two acute disorders are based on common principles. HUS is primarily a kidney disease and TTP also develops in the kidney and at neurological sites. In HUS thrombi formation is likely due to a deregulated complement activation and inappropriate platelet activity. In TTP thrombi formation occurs because of inappropriate processing of released multimers of von Willebrand Factor (vWF). Defining both the similarities and the unique features of each disorder will open up new ways and concepts that are relevant for diagnosis, for therapy, and for the prognostic outcome of kidney transplantations. Here we summarize the most relevant topics and timely issues that were presented and discussed at the 4th International Workshop on Thrombotic Microangiopathies held in Weimar in October 2009 (www.hus-ttp.de).

Entities:  

Mesh:

Year:  2011        PMID: 21671028     DOI: 10.1007/s00467-011-1923-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  58 in total

Review 1.  C3 glomerulopathy: a new classification.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi; Laure-Hélène Noël; H Terence Cook; Matthew C Pickering
Journal:  Nat Rev Nephrol       Date:  2010-07-06       Impact factor: 28.314

Review 2.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

3.  Streptococcus pneumoniae--associated hemolytic uremic syndrome: classification and the emergence of serotype 19A.

Authors:  Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatrics       Date:  2009-12-21       Impact factor: 7.124

4.  Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis.

Authors:  M Masilamani; R Nowack; T Witte; M Schlesier; K Warnatz; M O Glocker; H H Peter; H Illges
Journal:  Scand J Immunol       Date:  2004-12       Impact factor: 3.487

5.  Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

Authors:  Mihály Józsi; Stefanie Strobel; Hans-Martin Dahse; Wei-shih Liu; Peter F Hoyer; Martin Oppermann; Christine Skerka; Peter F Zipfel
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

6.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

7.  Biologically active ADAMTS13 is expressed in renal tubular epithelial cells.

Authors:  Minola Manea; Ramesh Tati; Jessica Karlsson; Zivile D Békássy; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

8.  Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.

Authors:  Nirmal K Banda; Brandt Levitt; Magdalena J Glogowska; Joshua M Thurman; Kazue Takahashi; Gregory L Stahl; Stephen Tomlinson; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

9.  The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.

Authors:  M-A Dragon-Durey; C Blanc; F Marliot; C Loirat; J Blouin; C Sautes-Fridman; W H Fridman; V Frémeaux-Bacchi
Journal:  J Med Genet       Date:  2009-05-11       Impact factor: 6.318

Review 10.  Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.

Authors:  M C Pickering; H T Cook
Journal:  Clin Exp Immunol       Date:  2008-02       Impact factor: 4.330

View more
  6 in total

1.  Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome.

Authors:  Kathrin Buder; Beatrice Latal; Samuel Nef; Thomas J Neuhaus; Guido F Laube; Giuseppina Spartà
Journal:  Pediatr Nephrol       Date:  2014-09-19       Impact factor: 3.714

2.  Long-term health-related quality of life and psychological adjustment in children after haemolytic-uraemic syndrome.

Authors:  Helene Werner; Kathrin Buder; Markus A Landolt; Thomas J Neuhaus; Guido F Laube; Giuseppina Spartà
Journal:  Pediatr Nephrol       Date:  2016-12-23       Impact factor: 3.714

Review 3.  The role of von Willebrand factor in thrombotic microangiopathy.

Authors:  Damien G Noone; Magdalena Riedl; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2017-07-26       Impact factor: 3.714

4.  Health-related quality of life and mental health in parents of children with hemolytic uremic syndrome.

Authors:  Kathrin Buder; Helene Werner; Markus A Landolt; Thomas J Neuhaus; Guido F Laube; Giuseppina Spartà
Journal:  Pediatr Nephrol       Date:  2015-12-23       Impact factor: 3.714

5.  Indicators of acute and persistent renal damage in adult thrombotic microangiopathy.

Authors:  Firuseh Dierkes; Nikolaos Andriopoulos; Christoph Sucker; Kathrin Kuhr; Markus Hollenbeck; Gerd R Hetzel; Volker Burst; Sven Teschner; Lars C Rump; Thomas Benzing; Bernd Grabensee; Christine E Kurschat
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

6.  Abrogation of immune complex glomerulonephritis by native carboxypeptidase and pharmacological antagonism of the C5a receptor.

Authors:  Jessy J Alexander; Lee D Chaves; Anthony Chang; Shruti Dighe; Alexander Jacob; Richard J Quigg
Journal:  Cell Mol Immunol       Date:  2015-07-13       Impact factor: 11.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.